Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G8CU
|
|||
| Drug Name |
COTI-2
|
|||
| Synonyms |
Coti-2; UNII-2BTA1O65BR; 2BTA1O65BR; 1039455-84-9; ZINC114475331; CS-8156; HY-19896; 1-Piperazinecarbothioic acid, 4-(2-pyridinyl)-, 2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide
Click to Show/Hide
|
|||
| Indication | Cervical cancer [ICD-11: 2C77.0; ICD-9: 180] | Phase 1 | [1] | |
| Endometrial cancer [ICD-11: 2C76; ICD-9: 182] | Phase 1 | [1] | ||
| Fallopian tube cancer [ICD-11: 2C74; ICD-10: C57.0] | Phase 1 | [1] | ||
| Head and neck cancer [ICD-11: 2D42] | Phase 1 | [1] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [1], [2] | ||
| Peritoneal cavity cancer [ICD-11: 2C51.Z] | Phase 1 | [1] | ||
| Company |
Cotinga Pharmaceuticals London, Canada
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H22N6S
|
|||
| Canonical SMILES |
C1CC2=C(C(=NNC(=S)N3CCN(CC3)C4=CC=CC=N4)C1)N=CC=C2
|
|||
| InChI |
1S/C19H22N6S/c26-19(23-22-16-7-3-5-15-6-4-10-21-18(15)16)25-13-11-24(12-14-25)17-8-1-2-9-20-17/h1-2,4,6,8-10H,3,5,7,11-14H2,(H,23,26)/b22-16+
|
|||
| InChIKey |
UTDAKQMBNSHJJB-CJLVFECKSA-N
|
|||
| CAS Number |
CAS 1039455-84-9
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.